These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 14672093)

  • 21. The history of antiretrovirals: key discoveries over the past 25 years.
    De Clercq E
    Rev Med Virol; 2009 Sep; 19(5):287-99. PubMed ID: 19714702
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Approval of a new nucleoside. Component of complete once daily regimen].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():91. PubMed ID: 15373067
    [No Abstract]   [Full Text] [Related]  

  • 23. I'm still the optimist.
    Burgess G
    Surviv News (Atlanta Ga); 2001 Dec; ():17. PubMed ID: 11802621
    [No Abstract]   [Full Text] [Related]  

  • 24. Changes in HIV-1 RNA plasma level in patients treated with foscarnet.
    Segondy M; Montes B; Delmas B; Leclercq C; Janbon F; Reynes J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Jan; 14(1):79-80. PubMed ID: 8989215
    [No Abstract]   [Full Text] [Related]  

  • 25. HIV: postponing initial treatment? Keep a close check on CD4+ cell count and viral load.
    Prescrire Int; 2004 Jun; 13(71):110. PubMed ID: 15233154
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A look ahead at this year's drug approvals.
    Proj Inf Perspect; 2007 Apr; (43):4-7. PubMed ID: 17684824
    [No Abstract]   [Full Text] [Related]  

  • 27. Opinion paper. Resistance to new anti-HIV agents: problems in the pathway of drug registration.
    Dalmau D; Klimkait T; Telenti A
    Antivir Ther; 2005; 10(7):867-72. PubMed ID: 16312184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs: implications for the development of therapeutic strategies.
    Demonté D; Quivy V; Colette Y; Van Lint C
    Biochem Pharmacol; 2004 Sep; 68(6):1231-8. PubMed ID: 15313421
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Virological characterization of patients treated early is able to control HIV-1 replication after multiple cycles of structured therapy interruption.
    Rozera G; Abbate I; D'Offizi G; Corpolongo A; Narciso P; Vlassi C; Martini F; Calcaterra S; Capobianchi MR
    J Med Virol; 2007 Aug; 79(8):1047-54. PubMed ID: 17597482
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment interruptions in HIV-infected subjects.
    Bongiovanni M; Casana M; Tincati C; d'Arminio Monforte A
    J Antimicrob Chemother; 2006 Sep; 58(3):502-5. PubMed ID: 16816398
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FDA grants tentative approval to first generic version of antiretroviral Viread.
    AIDS Patient Care STDS; 2008 Jan; 22(1):86. PubMed ID: 18453039
    [No Abstract]   [Full Text] [Related]  

  • 32. T-1249 development hits a snag.
    AIDS Clin Care; 2004 Feb; 16(2):15. PubMed ID: 15032178
    [No Abstract]   [Full Text] [Related]  

  • 33. Generic nucleoside approved.
    AIDS Patient Care STDS; 2005 Aug; 19(8):540. PubMed ID: 16163787
    [No Abstract]   [Full Text] [Related]  

  • 34. Regulatory issues and challenges in salvage therapy.
    Delaney M
    Res Initiat Treat Action; 2004; 10(1):29-30. PubMed ID: 15595171
    [No Abstract]   [Full Text] [Related]  

  • 35. HIV type 1 integrase inhibitors: from basic research to clinical implications.
    Jegede O; Babu J; Di Santo R; McColl DJ; Weber J; Quiñones-Mateu M
    AIDS Rev; 2008; 10(3):172-89. PubMed ID: 18820719
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A rare moment in time.
    Huff B
    GMHC Treat Issues; 2007; 21(1):12. PubMed ID: 17722333
    [No Abstract]   [Full Text] [Related]  

  • 37. Update on new antiretroviral drugs. An interview with Harold Kessler, M.D. by Matt Sharp.
    Kessler H
    Posit Aware; 2007; 18(6):22-4. PubMed ID: 18074429
    [No Abstract]   [Full Text] [Related]  

  • 38. HIV resistance and the developing world.
    Gupta RK; Pillay D
    Int J Antimicrob Agents; 2007 May; 29(5):510-7. PubMed ID: 17346940
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Maintaining reduced viral fitness and CD4 response in HIV-infected patients with viremia receiving a boosted protease inhibitor.
    Grant P; Taylor J; Cain P; Short W; Gallant J; Farthing C; Thal G; Coakley E; Zolopa A
    Clin Infect Dis; 2009 Mar; 48(5):680-2. PubMed ID: 19191657
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AIDS treatment. Drugmakers test restrictions on generics in U.S. programs.
    Cohen J
    Science; 2004 Oct; 306(5694):213. PubMed ID: 15472049
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.